Organon reports FY 2022 revenue $6.2B (-2% as-reported); Q4 GAAP EPS $0.42, provides 2023 guidance

Organon & Co.

2022-FY EPS reported $3.59 revenue$6,174,000,000

FY 2022 revenue $6.174B, down 2% as-reported, up 4% ex-FX; diluted GAAP EPS $3.59, non-GAAP adjusted $5.03.
Q4 2022 revenue $1.485B, down 7% as-reported, up 1% ex-FX; GAAP EPS $0.42, non-GAAP adjusted $0.81.
All three franchises grew on constant-currency basis in FY 2022; Nexplanon up 11% ex-FX, Biosimilars up 17% ex-FX.
Q4 included $36M inventory charges and $8M sales return reserve due to Heist facility market action.
2023 guidance: revenue $6.15B-$6.45B; Adjusted EBITDA margin 31%-33%; quarterly dividend $0.28/share declared.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Organon & Co. reported the fourth quarter and full year ended December 31, 2022 results: revenue $1,485 million, net income $108 million, EPS $0.42 per diluted share.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: $1,485 million
Net income: $108 million
EPS: $0.42 per diluted share
Result: reported results

Exact text from the filing

For the fourth quarter of 2022, total revenue was $1,485 million, a decrease of 7% as-reported and an increase of 1% excluding the impact of foreign currency (ex-FX), compared with the fourth quarter of 2021.

View on SEC.gov

Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-23-022617

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.